Harvard Bioscience Announces Fourth Quarter 2020 Financial Results

Rhea-AI Summary

Harvard Bioscience reported Q4 2020 revenue of $31.0 million, returning to pre-COVID levels, aided by a 19% year-over-year increase in preclinical product revenue. Operating income rose to $2.8 million, with a GAAP operating margin of 8.9%. The company successfully refinanced its credit facility, expected to save approximately $3 million annually in interest. For 2021, Harvard anticipates revenue growth of 8% to 12% and adjusted operating margins in the mid-to-upper teens, driven by new products and improved profit mix.

Positive

• Revenue returned to pre-COVID levels at $31.0 million.
• 19% increase in preclinical product revenue over Q4 2019.
• Operating income rose to $2.8 million, improving GAAP operating margin to 8.9%.
• Successfully refinanced credit facility, saving approximately $3 million annually in interest.
• Forecasting revenue growth of 8% to 12% for 2021.

Negative

• GAAP diluted loss per share of ($0.02).

Sales effectiveness focus with disciplined cost management results in improved revenues and margins while reducing debt

• Revenue returns to pre-Covid19 levels on strong CRO/pharma sales
• Operating margin increased year-over-year on GAAP and an adjusted basis
• New debt facility significantly reduces annual interest expense
  

HOLLISTON, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the three months and year ended December 31, 2020.

Jim Green, Chairman and CEO said, “Our fourth quarter demonstrated the benefits of our sales effectiveness focus as we delivered revenue at pre-Covid levels, or $31.0 million. Our preclinical product revenue increased 19% over Q4 2019. In addition, we are very pleased to have successfully refinanced our credit facility which is expected to save approximately $3M annually in cash interest based upon current debt levels and provides numerous other enhancements compared to the former facility.”

Green concluded, “With strong CRO/Pharma growth and recovering academic lab sales, we expect revenue to grow 8 to 12% compared to 2020. In addition, exciting new products along with removal of lower value offerings is expected to improve our profit mix, delivering adjusted operating margins in the mid-to-upper teens in 2021. We believe the strong 2020 ending and our focus on growth and new exciting products puts 2021 on plan to creating the growth oriented profitable platform we envisioned.”

 

	Quarterly Financial Results Summary		Q4'20		Q3'20		Q4'19
	Revenue		$31.0 million		$24.0 million		$31.0 million
	Operating Income (GAAP)		$2.8 million		$0.2 million		$1.6 million
	Adjusted Operating Income		$5.8 million		$3.6 million		$5.6 million
	Operating Margin (GAAP)		8.9%		0.8%		5.3%
	Adjusted Operating Margin		18.7%		14.8%		18.1%
	Diluted (Loss) Earnings Per Share (GAAP)		($0.02)		($0.03)		$0.01
	Adjusted Diluted Earnings Per Share		$0.08		$0.04		$0.08
	Net Debt*		$41.1 million		$41.6 million		$46.7 million
	* Debt outstanding less cash and cash equivalents

Please refer to the exhibits below for a reconciliation of certain non-GAAP to GAAP financial measures, including operating income, net income and loss, and diluted earnings per share. Please see “Use of Non-GAAP Financial Information” for additional information regarding our use of such adjusted financial information.

Webcast and Conference Call Details

Harvard Bioscience will be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID# 4375572.

The conference call will be simultaneously webcast and can be accessed through the Harvard Bioscience website. A slide presentation that will be referenced during the webcast will be posted to our Investor Relations website shortly before the webcast begins. To listen to the webcast, log on to the webcast at: http://investor.harvardbioscience.com/ and click on the Earnings Call icon.

Use of Non-GAAP Financial Information

In this press release, we have included non-GAAP financial information including adjusted operating income, adjusted net income, and adjusted diluted earnings per share. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income primarily resulting from purchase accounting or events that we do not believe are related to the underlying operations of the business such as amortization of intangibles related to acquisitions, costs related to acquisition, disposition and integration initiatives, impairment charges, severance, restructuring and other business transformation expenses, and stock-based compensation expense. They also exclude the tax impact of the reconciling items. This non-GAAP financial information approximates information used by our management to internally evaluate the operating results of the Company. Tabular reconciliations of our adjusted operating income, adjusted net income (loss), and adjusted earnings (loss) per diluted share are included as exhibits below in this press release.

The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information.

About Harvard Bioscience

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Our customers range from renowned academic institutions and government laboratories, to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as "will," "guidance," "objectives," "optimistic," "potential," "future," "expects," "plans," "estimates," "continue," "drive," "strategy," "potential," "potentially," "growth," "long-term," "projects," "projected," "intends," "believes," "goals," "sees," "seek," "develop" "possible" "new," "emerging," "opportunity," "pursue" and similar expressions that do not relate to historical matters. Forward-looking statements in this press release or that may be made during our conference call may include, but are not limited to, statements or inferences about the Company's or management's beliefs or expectations, the Company's anticipated future revenues and earnings, the strength of the Company's market position and business model, industry outlook, the impact of the COVID-19 pandemic on the Company’s business, the Company's business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company's current products, or products it is developing or intends to develop, and the Company's plans, objectives and intentions that are not historical facts. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, and in our Quarterly Reports on Form 10-Q issued in 2020 and in our other filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein may cause the Company's actual results to differ materially from those in the forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

For investor inquiries, please contact Michael A. Rossi, Chief Financial Officer at (508) 893-8999.

																			Exhibit 1
		HARVARD BIOSCIENCE, INC.
		Consolidated Statements of Operations
		(unaudited, in thousands, except per share data)
										Three Months Ended
											December 31, 2020				September 30, 2020				December 31, 2019
			Revenues							$	30,984			$	24,037			$	30,972
			Cost of revenues								13,276				10,542				13,738
				Gross profit							17,708				13,495				17,234
			Operating expenses:
				Sales and marketing expenses							5,470				4,588				5,894
				General and administrative expenses							5,681				5,399				5,545
				Research and development expenses							2,349				1,949				2,645
				Amortization of intangible assets							1,452				1,377				1,457
				Impairment charges							-				-				59
			Total operating expenses								14,952				13,313				15,600
			Operating income								2,756				182				1,634
			Other expense:
				Interest expense							(1,094	)			(1,205	)			(1,281	)
				Debt extinguishment and related costs							(1,876	)			-				-
				Other expense, net							(334	)			(392	)			(255	)
			Total other expense								(3,304	)			(1,597	)			(1,536	)
			(Loss) income before income taxes								(548	)			(1,415	)			98
			Income tax expense (benefit)								67				(317	)			(452	)
			Net (loss) income							$	(615	)		$	(1,098	)		$	550
			(Loss) earnings per common share:
				Basic						$	(0.02	)		$	(0.03	)		$	0.01
				Diluted						$	(0.02	)		$	(0.03	)		$	0.01
			Weighted average common shares:
				Basic							39,021				38,920				38,068
				Diluted							39,021				38,920				39,070

																Exhibit 1.1
				HARVARD BIOSCIENCE, INC.
				Consolidated Statements of Operations
				(unaudited, in thousands, except per share data)
											Year Ended December 31,
												2020				2019
				Revenues							$	102,100			$	116,176
				Cost of revenues								44,059				51,854
					Gross profit							58,041				64,322
				Operating expenses:
					Sales and marketing expenses							19,916				23,264
					General and administrative expenses							23,509				22,760
					Research and development expenses							8,685				10,715
					Amortization of intangible assets							5,710				5,746
					Impairment charges							-				1,460
				Total operating expenses								57,820				63,945
				Operating income								221				377
				Other expense:
					Interest expense							(4,831	)			(5,410	)
					Debt extinguishment and related costs							(1,876	)			-
					Other expense, net							(806	)			(469	)
				Total other expense								(7,513	)			(5,879	)
				Loss before income taxes								(7,292	)			(5,502	)
				Income tax expense (benefit)								518				(815	)
				Net loss							$	(7,810	)		$	(4,687	)
				Loss per common share:
					Basic and diluted						$	(0.20	)		$	(0.12	)
				Weighted average common shares:
					Basic and diluted							38,640				37,814

								Exhibit 2
		HARVARD BIOSCIENCE, INC.
		Condensed Consolidated Balance Sheets
		(unaudited, in thousands)
					December 31, 2020			December 31, 2019
			Assets
			Cash and cash equivalents	$	8,317		$	8,335
			Accounts receivables		17,766			20,704
			Inventories		22,262			22,061
			Other current assets		3,355			2,472
			Total current assets		51,700			53,572
			Property, plant and equipment		3,960			4,776
			Goodwill and other intangibles		91,741			95,786
			Other long-term assets		8,853			10,736
			Total assets	$	156,254		$	164,870
			Liabilities and Stockholders' Equity
			Current portion, long-term debt	$	1,721		$	6,900
			Other current liabilities		19,332			18,412
			Total current liabilities		21,053			25,312
			Long-term debt		46,286			46,917
			Other long-term liabilities		12,234			10,947
			Stockholders’ equity		76,681			81,694
			Total liabilities and stockholders’ equity	$	156,254		$	164,870

									Exhibit 3
		HARVARD BIOSCIENCE, INC.
		Condensed Consolidated Statements of Cash Flows
		(unaudited, in thousands)
					Year Ended December 31,
					2020				2019
			Cash flows from operating activities:
			Net loss	$	(7,810	)		$	(4,687	)
			Adjustments to operating cash flows		13,035				12,690
			Changes in operating assets and liabilities		4,106				42
			Net cash provided by operating activities		9,331				8,045
			Cash flows from investing activities:
			Additions to property, plant and equipment		(1,152	)			(1,216	)
			Disposition of business		-				1,002
			Other investing activities		(250	)			(15	)
			Net cash used in investing activities		(1,402	)			(229	)
			Cash flows from financing activities:
			Proceeds from borrowings		61,315				4,300
			Repayments of debt		(66,912	)			(11,703	)
			Payments of debt extinguishment and issuance costs		(1,897	)			-
			Other financing activities		(473	)			(221	)
			Net cash used in financing activities		(7,967	)			(7,624	)
			Effect of exchange rate changes on cash		20				(30	)
			(Decrease) increase in cash and cash equivalents		(18	)			162
			Cash and cash equivalents at the beginning of year		8,335				8,173
			Cash and cash equivalents at the end of year	$	8,317			$	8,335

												Exhibit 4
	HARVARD BIOSCIENCE, INC.
	Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
	(in thousands, except per share data)
			Three Months Ended
				December 31,				September 30,				December 31,
				2020				2020				2019
		GAAP operating income	$	2,756			$	182			$	1,634
		Stock-based compensation expense		1,006				1,079				841
		Severance, restructuring and transformation costs		532				876				1,551
		Acquired assets amortization and impairments		1,503				1,428				1,575
		Adjusted operating income	$	5,797			$	3,565			$	5,601
		GAAP operating margin		8.9	%			0.8	%			5.3	%
		Adjusted operating margin		18.7	%			14.8	%			18.1	%
		GAAP net (loss) income	$	(615	)		$	(1,098	)		$	550
		Stock-based compensation expense		1,006				1,079				841
		Severance, restructuring and transformation costs		532				876				1,551
		Debt extinguishment and related costs		1,876				-				-
		Acquired assets amortization and impairments		1,503				1,428				1,575
		Income taxes (A)		(1,034	)			(823	)			(1,472	)
		Adjusted net income	$	3,268			$	1,462			$	3,045
		GAAP (loss) earnings per diluted share	$	(0.02	)		$	(0.03	)		$	0.01
		Adjusted items after tax per share assuming dilution		0.10				0.07				0.07
		Adjusted earnings per diluted share	$	0.08			$	0.04			$	0.08
		Weighted average diluted common shares:
		GAAP		39,021				38,920				38,068
		Adjusted		40,810				40,307				39,070
		(A)    Income taxes includes the tax effect of the adjustments to GAAP results.

							Exhibit 4.1
	HARVARD BIOSCIENCE, INC.
	Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
	(in thousands, except per share data)
			Year Ended December 31,
				2020			2019
		GAAP operating (loss) income	$	221		$	377
		Stock-based compensation expense		3,647			3,030
		Severance, restructuring and transformation costs		4,166			3,943
		Acquired assets amortization and impairments		5,920			7,503
		Adjusted operating income	$	13,954		$	14,853
		GAAP operating margin		0.2%			0.3%
		Adjusted operating margin		13.7%			12.8%
		GAAP net loss	$	(7,810)		$	(4,687)
		Stock-based compensation expense		3,647			3,030
		Severance, restructuring and transformation costs		4,166			3,943
		Debt extinguishment and related costs		1,876			-
		Acquired assets amortization and impairments		5,920			7,503
		Income taxes (A)		(1,469)			(2,766)
		Adjusted net income	$	6,330		$	7,023
		GAAP loss per diluted share	$	(0.20)		$	(0.12)
		Adjusted items after tax per share assuming dilution		0.36			0.30
		Adjusted earnings per diluted share	$	0.16		$	0.18
		Weighted average diluted common shares:
		GAAP		38,640			37,814
		Adjusted		39,985			38,373
		(A)    Income taxes includes the tax effect of the adjustments to GAAP results.

FAQ

What were Harvard Bioscience's Q4 2020 earnings results?

Harvard Bioscience reported Q4 2020 revenue of $31.0 million and an operating income of $2.8 million.

What is the revenue growth forecast for Harvard Bioscience in 2021?

Harvard Bioscience expects revenue growth of 8% to 12% compared to 2020.

How much did Harvard Bioscience save from refinancing its credit facility?

The refinancing is expected to save approximately $3 million annually in interest.

What was the diluted earnings per share for Harvard Bioscience in Q4 2020?

Harvard Bioscience reported a GAAP diluted loss per share of ($0.02) in Q4 2020.